Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vorapaxar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R known ✓ | P25116 | 20/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vorapaxar SCHEMBL14203542 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203639 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203540 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203571 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203496 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL24988797 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203549 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203651 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL22122697 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 | |
| Vorapaxar SCHEMBL14203666 | 1.00 | F2R (1.00) | F2RABCB11ADORA3CHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085923-A1 | Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine | SCHERING CORPORATION | 2008-04-10 | — | — | US | disclosed |
| US-20080085923-A1 | Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine | SCHERING CORPORATION | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085923-A1 | Thrombin Receptor Antagonists Based On The Modified Tricyclic Unit Of Himbacine | PTAFR, TBXA2R, BDKRB1 | F2R 5/4885ABCB11 1602/4885ADORA3 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.